Zolgensma’s Pay Model Avoids Medicaid Best Price Pitfall

May 30, 2019
The pay model for the world’s most expensive drug, Zolgensma, lets insurers pay less for the gene therapy when it doesn’t work without triggering Medicaid best price, a policy that has frustrated development of value-based pay arrangements, said a spokesperson for Zolgensma’s maker AveXis. The Zolgensma pay model is unique, but it could be applied to other expensive gene therapies, according to a spokesperson for Accredo, which developed the pay model. FDA approved Zolgensma last week, and the Novartis company...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.